AI Terminal
Achiko AG
Share Issue/Capital Change • Dec 14, 2021
804_rns_2021-12-14_34a57ffb-73a3-452a-a629-c17c3d7c1fc8.html
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 14 December 2021 18:30
Achiko completes share capital increase
Achiko AG / Key word(s): Miscellaneous
14-Dec-2021 / 18:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Achiko completes share capital increase
Zurich, 14 December 2021: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SWX: ACHI, ISIN CH0522213468) announces that its share capital recorded in the commercial register has been increased by 10,081,666 shares to 118,985,566 shares to satisfy claims from a share lending relied on in connection with a private placement. The new shares have been issued out of the existing authorized capital.
ABOUT ACHIKO AG
Achiko creates and develops new innovations in healthcare technology through its biotechnology division, AptameX TM , and its sister digital mobile health technology division, Teman Sehat TM . The Company has created a unique healthtech capability that provides user-friendly diagnostic testing integrated with a digital passport solution for the management of Covid-19.
AptameX comprises of DNA aptamer-based technology that is cost-effective, chemically synthesised and widely applicable to the evolving diagnostic field of healthcare. Together with the digital mobile health app Teman Sehat, Achiko is developing potential technologies that seek to deliver rapid, affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications. The AptameX technology is licensed from Regenacellx.sl and Achiko has exclusive commercialisation rights.
Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul and Singapore.
Further information can be found at www.achiko.com .
Media contacts:
ACHIKO AG
Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
T: +41 44 266 67 67
U.S. & Global
Jeanene Timberlake
RooneyPartners
T: +1 646 770 8858
*Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*
End of ad hoc announcement
| Language: | English |
| Company: | Achiko AG |
| Tessinerplatz 7 | |
| 8002 Zurich | |
| Switzerland | |
| E-mail: | [email protected] |
| Internet: | https://www.achiko.com/ |
| ISIN: | CH0522213468 |
| Valor: | 48788430 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1257797 |
| End of Announcement | EQS News Service |